AstraZeneca’s (AZN) “Hold” Rating Reiterated at Liberum Capital

AstraZeneca (LON:AZN)‘s stock had its “hold” rating reaffirmed by equities researchers at Liberum Capital in a report issued on Monday. They currently have a GBX 5,000 ($69.08) price target on the biopharmaceutical company’s stock. Liberum Capital’s price objective suggests a potential upside of 4.17% from the company’s previous close.

Several other research analysts also recently commented on AZN. HSBC increased their price objective on AstraZeneca from GBX 4,340 ($59.96) to GBX 4,380 ($60.51) and gave the company a “reduce” rating in a research note on Thursday, November 16th. Jefferies Group reissued a “hold” rating and issued a GBX 5,100 ($70.46) price objective on shares of AstraZeneca in a research note on Thursday, November 16th. JPMorgan Chase & Co. set a GBX 4,800 ($66.32) price objective on AstraZeneca and gave the company a “neutral” rating in a research note on Thursday, November 30th. Morgan Stanley reissued an “equal weight” rating and issued a GBX 5,000 ($69.08) price objective on shares of AstraZeneca in a research note on Friday, December 1st. Finally, Shore Capital reissued a “hold” rating on shares of AstraZeneca in a research note on Monday, December 4th. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Hold” and an average target price of GBX 5,199.70 ($71.84).

AstraZeneca (LON AZN) traded up GBX 14.50 ($0.20) during midday trading on Monday, reaching GBX 4,800 ($66.32). The company had a trading volume of 1,664,175 shares, compared to its average volume of 2,300,000. AstraZeneca has a 1 year low of GBX 4,260 ($58.86) and a 1 year high of GBX 5,520 ($76.26). The firm has a market cap of $60,790.00 and a P/E ratio of 2,823.53.

In other AstraZeneca news, insider Philip A. J. Broadley acquired 415 shares of the business’s stock in a transaction that occurred on Friday, February 2nd. The stock was purchased at an average cost of GBX 4,846 ($66.95) per share, with a total value of £20,110.90 ($27,785.16).

WARNING: “AstraZeneca’s (AZN) “Hold” Rating Reiterated at Liberum Capital” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.

Leave a Reply